Atul Humar

Atul Humar's AcademicInfluence.com Rankings

Atul Humar

Engineering

#6473

World Rank

#7803

Historical Rank

Biomedical Engineering

#577

World Rank

#587

Historical Rank

Electrical Engineering

#1932

World Rank

#2034

Historical Rank

Applied Physics

#2071

World Rank

#2110

Historical Rank

engineering Degrees

Download Badge

Engineering

Why Is Atul Humar Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Atul Humar's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation (2010) (794)
Efficacy and Safety of Valganciclovir vs. Oral Ganciclovir for Prevention of Cytomegalovirus Disease in Solid Organ Transplant Recipients (2004) (789)
Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. (2013) (591)
International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. (2010) (443)
American Society of Transplantation Recommendations for Screening, Monitoring and Reporting of Infectious Complications in Immunosuppression Trials in Recipients of Organ Transplantation (2006) (437)
Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients (2021) (368)
Interferon-Mediated Immunopathological Events Are Associated with Atypical Innate and Adaptive Immune Responses in Patients with Severe Acute Respiratory Syndrome (2007) (355)
Outcomes from pandemic influenza A H1N1 infection in recipients of solid-organ transplants: a multicentre cohort study. (2010) (329)
Cytomegalovirus in solid organ transplant recipients—Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice (2019) (295)
Cytomegalovirus in Solid Organ Transplant Recipients (2009) (286)
Clinical Impact of Community‐Acquired Respiratory Viruses on Bronchiolitis Obliterans After Lung Transplant (2005) (245)
Parasight F test compared with the polymerase chain reaction and microscopy for the diagnosis of Plasmodium falciparum malaria in travelers. (1997) (235)
An immune reconstitution syndrome-like illness associated with Cryptococcus neoformans infection in organ transplant recipients. (2005) (225)
Cryptococcus neoformans in organ transplant recipients: impact of calcineurin-inhibitor agents on mortality. (2007) (221)
Clinical utility of quantitative cytomegalovirus viral load determination for predicting cytomegalovirus disease in liver transplant recipients. (1999) (221)
Assessment of cytomegalovirus-specific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients: a multicenter cohort study. (2013) (219)
Cell‐Mediated Immunity to Predict Cytomegalovirus Disease in High‐Risk Solid Organ Transplant Recipients (2009) (219)
RNA interference therapy in lung transplant patients infected with respiratory syncytial virus. (2011) (197)
COVID-19: A global transplant perspective on successfully navigating a pandemic (2020) (193)
Extended Valganciclovir Prophylaxis in D+/R− Kidney Transplant Recipients is Associated With Long-Term Reduction in Cytomegalovirus Disease: Two-Year Results of the IMPACT Study (2010) (182)
West Nile virus infection in 2002: morbidity and mortality among patients admitted to hospital in southcentral Ontario. (2003) (178)
Cytomegalovirus (CMV) virus load kinetics to predict recurrent disease in solid-organ transplant patients with CMV disease. (2002) (176)
Changes in the spectrum and risk factors for invasive candidiasis in liver transplant recipients: prospective, multicenter, case-controlled study1 (2003) (172)
Prospective randomized trial of 10% povidone-iodine versus 0.5% tincture of chlorhexidine as cutaneous antisepsis for prevention of central venous catheter infection. (2000) (164)
Nucleic Acid Testing (NAT) of Organ Donors: Is the ‘Best’ Test the Right Test? A Consensus Conference Report (2010) (162)
A 2010 working formulation for the standardization of definitions of infections in cardiothoracic transplant recipients (2011) (161)
Absence of cytomegalovirus-resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients. (2004) (160)
A Prospective Molecular Surveillance Study Evaluating the Clinical Impact of Community-Acquired Respiratory Viruses in Lung Transplant Recipients (2010) (153)
Clinical Utility of Cytomegalovirus (CMV) Serology Testing in High‐risk CMV D+/R− Transplant Recipients (2005) (152)
Pulmonary cryptococcosis in solid organ transplant recipients: clinical relevance of serum cryptococcal antigen. (2008) (144)
Pharmacodynamics of Oral Ganciclovir and Valganciclovir in Solid Organ Transplant Recipients (2005) (144)
Severe Acute Respiratory Syndrome (SARS) in a Liver Transplant Recipient and Guidelines for Donor SARS Screening (2003) (138)
Guidance on Novel Influenza A/H1N1 in Solid Organ Transplant Recipients † (2010) (133)
State-of-the-art monitoring of cytomegalovirus-specific cell-mediated immunity after organ transplant: a primer for the clinician. (2012) (130)
Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial (2021) (129)
Clinical Utility of Cytomegalovirus Cell-Mediated Immunity in Transplant Recipients With Cytomegalovirus Viremia (2012) (128)
Randomized, double-blind, controlled trial of pneumococcal vaccination in renal transplant recipients. (2003) (126)
A 5-Year Prospective Multicenter Evaluation of Influenza Infection in Transplant Recipients (2018) (121)
Diagnosis and Management of Tuberculosis in Transplant Donors: A Donor‐Derived Infections Consensus Conference Report † (2012) (115)
Community-acquired West Nile virus infection in solid-organ transplant recipients (2004) (114)
Pharmacokinetic Profile of Ganciclovir After its Oral Administration and From its Prodrug, Valganciclovir, in Solid Organ Transplant Recipients (2005) (114)
A Report of the Lisbon Conference on the Care of the Kidney Transplant Recipient (2007) (114)
Comparison of Quantiferon‐TB Gold With Tuberculin Skin Test for Detecting Latent Tuberculosis Infection Prior to Liver Transplantation (2007) (113)
A Double-Blind, Randomized Trial of High-Dose vs Standard-Dose Influenza Vaccine in Adult Solid-Organ Transplant Recipients (2018) (113)
Clinical impact of human herpesvirus 6 infection after liver transplantation. (2002) (111)
A Surveillance Study of Adenovirus Infection in Adult Solid Organ Transplant Recipients (2005) (110)
Invasive Pneumococcal Disease in Solid Organ Transplant Recipients—10‐Year Prospective Population Surveillance (2007) (109)
Mycobacterium abscessus infections in lung transplant recipients: the international experience. (2006) (108)
Immunogenicity of Pneumococcal Vaccine in Renal Transplant Recipients—Three Year Follow‐up of a Randomized Trial (2006) (108)
Levofloxacin for BK virus prophylaxis following kidney transplantation: a randomized clinical trial. (2014) (108)
Clinical Utility of Cytomegalovirus Viral Load Testing for Predicting CMV Disease in D+/R‐ Solid Organ Transplant Recipients (2004) (108)
Human herpesvirus-6 is associated with cytomegalovirus reactivation in liver transplant recipients. (2000) (107)
Clinical immune-monitoring strategies for predicting infection risk in solid organ transplantation (2014) (105)
Immunogenicity of Quadrivalent Human Papillomavirus Vaccine in Organ Transplant Recipients (2013) (105)
An Interventional Study Using Cell‐Mediated Immunity to Personalize Therapy for Cytomegalovirus Infection After Transplantation (2017) (104)
Impact of genetic polymorphisms in cytomegalovirus glycoprotein B on outcomes in solid-organ transplant recipients with cytomegalovirus disease. (2009) (102)
Herpesvirus infections in solid organ transplant patients at high risk of primary cytomegalovirus disease. (2005) (98)
Interactions Between Cytomegalovirus, Human Herpesvirus‐6, and the Recurrence of Hepatitis C After Liver Transplantation (2002) (98)
A Trial of Valganciclovir Prophylaxis for Cytomegalovirus Prevention in Lung Transplant Recipients (2005) (97)
Low-Virulence Citrobacter Species Encode Resistance to Multiple Antimicrobials (2002) (96)
A Randomized Trial of Ganciclovir versus Ganciclovir Plus Immune Globulin for Prophylaxis Against Epstein-Barr Virus Related Posttransplant Lymphoproliferative Disorder (2006) (95)
Epidemiology and Molecular Characterization of Bacteremia Due to Carbapenem‐Resistant Klebsiella pneumoniae in Transplant Recipients (2013) (94)
Allograft loss in renal transplant recipients with cryptococcus neoformans associated immune reconstitution syndrome. (2005) (93)
The Role of Antiviral Prophylaxis for the Prevention of Epstein–Barr Virus–Associated Posttransplant Lymphoproliferative Disease in Solid Organ Transplant Recipients: A Systematic Review (2017) (93)
Elevated serum cytokines are associated with cytomegalovirus infection and disease in bone marrow transplant recipients. (1999) (92)
Calcineurin Inhibitor Agents Interact Synergistically with Antifungal Agents In Vitro against Cryptococcus neoformans Isolates: Correlation with Outcome in Solid Organ Transplant Recipients with Cryptococcosis (2007) (92)
IL-28B is a Key Regulator of B- and T-Cell Vaccine Responses against Influenza (2014) (91)
Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir (2009) (89)
A Seroprevalence Study of West Nile Virus Infection in Solid Organ Transplant Recipients (2004) (87)
Is surveillance for multidrug-resistant enterobacteriaceae an effective infection control strategy in the absence of an outbreak? (2002) (86)
Humoral and cellular immune response and safety of two-dose SARS-CoV-2 mRNA-1273 vaccine in solid organ transplant recipients (2021) (86)
Invasive pneumococcal disease in adult hematopoietic stem cell transplant recipients: a decade of prospective population-based surveillance (2008) (84)
Randomized Controlled Trial of High‐Dose Intradermal Versus Standard‐Dose Intramuscular Influenza Vaccine in Organ Transplant Recipients (2013) (83)
The Clinical Utility of Whole Blood Versus Plasma Cytomegalovirus Viral Load Assays for Monitoring Therapeutic Response (2011) (82)
Travel patterns and risk behavior in solid organ transplant recipients. (2004) (80)
Cytomegalovirus (CMV) glycoprotein B genotypes and response to antiviral therapy, in solid-organ-transplant recipients with CMV disease. (2003) (79)
Impact of infectious disease consultation on the clinical and economic outcomes of solid organ transplant recipients admitted for infectious complications. (2014) (79)
Lamivudine for hepatitis B in liver transplantation: a single-center experience. (2000) (78)
Incidence and clinical characteristics of herpes zoster after lung transplantation. (2008) (77)
A randomized, double-blind trial of pneumococcal vaccination in adult allogeneic stem cell transplant donors and recipients. (2007) (77)
Immunomodulatory Function of Interleukin 28B during primary infection with cytomegalovirus. (2014) (77)
Risk Factors for Cytomegalovirus Viremia and Disease Developing after Prophylaxis in High-Risk Solid-Organ Transplant Recipients (2004) (73)
Inactivating hepatitis C virus in donor lungs using light therapies during normothermic ex vivo lung perfusion (2019) (73)
Unrecognized pretransplant and donor‐derived cryptococcal disease in organ transplant recipients. (2010) (71)
Antifungal Management Practices and Evolution of Infection in Organ Transplant Recipients with Cryptococcus Neoformans Infection (2005) (71)
A longitudinal molecular surveillance study of human polyomavirus viremia in heart, kidney, liver, and pancreas transplant patients. (2005) (70)
Prevention of viral transmission during lung transplantation with hepatitis C-viraemic donors: an open-label, single-centre, pilot trial. (2020) (68)
An Assessment of Herpesvirus Co‐infections in Patients with CMV Disease: Correlation with Clinical and Virologic Outcomes (2009) (67)
Virologic suppression measured by a cytomegalovirus (CMV) DNA test calibrated to the World Health Organization international standard is predictive of CMV disease resolution in transplant recipients. (2013) (66)
An assessment of donor-to-recipient transmission patterns of human cytomegalovirus by analysis of viral genomic variants. (2009) (66)
Immunogenicity and Safety of an Intradermal Boosting Strategy for Vaccination Against Influenza in Lung Transplant Recipients (2007) (65)
An International Survey of Cytomegalovirus Management Practices in Lung Transplantation (2010) (65)
Cytomegalovirus disease recurrence after ganciclovir treatment in kidney and kidney-pancreas transplant recipients. (1999) (65)
A randomized, double-blind, placebo-controlled trial to evaluate the prime-boost strategy for pneumococcal vaccination in adult liver transplant recipients. (2008) (64)
Central Nervous System Cryptococcosis in Solid Organ Transplant Recipients: Clinical Relevance of Abnormal Neuroimaging Findings (2008) (62)
Immunolocalisation of Burkholderia cepacia in the lungs of cystic fibrosis patients. (2001) (61)
A prospective assessment of valganciclovir for the treatment of cytomegalovirus infection and disease in transplant recipients. (2005) (60)
Targeted Versus Universal Antifungal Prophylaxis Among Liver Transplant Recipients (2015) (59)
Concurrent Genotyping and Quantitation of Cytomegalovirus gB Genotypes in Solid-Organ-Transplant Recipients by Use of a Real-Time PCR Assay (2008) (58)
Lipid formulations of amphotericin B significantly improve outcome in solid organ transplant recipients with central nervous system cryptococcosis. (2009) (57)
The production of transgenic pigs for potential use in clinical xenotransplantation: microbiological evaluation (2002) (57)
Clinical Utility of Molecular Surveillance for Cytomegalovirus After Antiviral Prophylaxis in High-Risk Solid Organ Transplant Recipients (2011) (56)
Bacteremia in Lung Transplant Recipients in the Current Era (2006) (56)
Randomized Controlled Trial of Adjuvanted Versus Nonadjuvanted Influenza Vaccine in Kidney Transplant Recipients (2016) (56)
Use of Viral Load as a Surrogate Marker in Clinical Studies of Cytomegalovirus in Solid Organ Transplantation: A Systematic Review and Meta-analysis (2018) (55)
Canadian Society of Transplantation and Canadian Society of Nephrology commentary on the 2009 KDIGO clinical practice guideline for the care of kidney transplant recipients. (2010) (54)
Fortnightly Review: Evaluating fever in travellers returning from tropical countries (1996) (54)
Reactivation of Viruses in Solid Organ Transplant Patients Receiving Cytomegalovirus Prophylaxis (2006) (54)
Short-course, direct-acting antivirals and ezetimibe to prevent HCV infection in recipients of organs from HCV-infected donors: a phase 3, single-centre, open-label study. (2020) (54)
Cytomegalovirus glycoprotein B genotype does not correlate with outcomes in liver transplant patients. (2002) (53)
Delay of Adequate Empiric Antibiotic Therapy Is Associated with Increased Mortality among Solid‐Organ Transplant Patients (2009) (52)
Delayed-interval BNT162b2 mRNA COVID-19 vaccination enhances humoral immunity and induces robust T cell responses (2022) (52)
Cutaneous cryptococcosis in solid organ transplant recipients. (2010) (49)
Lack of Association Between ß-herpesvirus Infection and Bronchiolitis Obliterans Syndrome in Lung Transplant Recipients in the Era of Antiviral Prophylaxis (2009) (49)
Neutralization against Omicron variant in transplant recipients after three doses of mRNA vaccine (2022) (48)
Low-dose intradermal versus intramuscular trivalent inactivated seasonal influenza vaccine in lung transplant recipients. (2011) (48)
Epstein-Barr virus infection in transplant recipients: Summary of a workshop on surveillance, prevention and treatment. (2002) (46)
Differentiation and quantitation of human herpesviruses 6A, 6B and 7 by real-time PCR. (2003) (46)
Canadian Society of Nephrology Commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis: management of nephrotic syndrome in children. (2014) (45)
Solid organ transplant patients: are there opportunities for antimicrobial stewardship? (2016) (43)
Effects of the Intensity of Immunosuppressive Therapy on Outcome of Treatment for CMV Disease in Organ Transplant Recipients (2010) (42)
Systematic integrative analysis of gene expression identifies HNF4A as the central gene in pathogenesis of non-alcoholic steatohepatitis (2017) (42)
Assessment of Adenovirus Infection in Adult Lung Transplant Recipients Using Molecular Surveillance (2006) (41)
Impact of Immunosuppression on the Metagenomic Composition of the Intestinal Microbiome: a Systems Biology Approach to Post-Transplant Diabetes (2017) (41)
Fatal Falciparum malaria in Canadian travellers. (1996) (40)
Emergence of Aspergillus calidoustus Infection in the Era of Posttransplantation Azole Prophylaxis (2012) (39)
Recurrence of CMV Infection and the Effect of Prolonged Antivirals in Organ Transplant Recipients (2017) (39)
Probable interaction between efavirenz and cyclosporine. (2002) (38)
Evaluation of a Novel Global Immunity Assay to Predict Infection in Organ Transplant Recipients (2018) (38)
Analysis and clinical correlation of genetic variation in cytomegalovirus (2012) (37)
Late Cytomegalovirus Transmission and Impact of T‐Depletion in Clinical Islet Transplantation (2011) (37)
Emerging viral infections in transplant recipients (2005) (37)
Comparison of the Effect of Standard and Novel Immunosuppressive Drugs on CMV-Specific T-Cell Cytokine Profiling (2013) (37)
The production of transgenic pigs for potential use in clinical xenotransplantation: baseline clinical pathology and organ size studies (2002) (36)
Pneumocystis jirovecii pneumonia after rituximab therapy for antibody‐mediated rejection in a renal transplant recipient (2009) (36)
Polyomavirus Infection and Acute Vascular Rejection in a Kidney Allograft: Coincidence or Mimicry? (2003) (36)
Successful Lung Transplantation From Hepatitis C Positive Donor to Seronegative Recipient (2017) (36)
Donor‐Derived Bacteremia in Liver Transplant Recipients Despite Antibiotic Prophylaxis (2013) (35)
A call to routinely test lower respiratory tract samples for SARS-CoV-2 in lung donors (2021) (35)
Living related donor pancreas and pancreas-kidney transplantation. (1997) (35)
Outcome of Latent Tuberculosis Infection in Solid Organ Transplant Recipients Over a 10-Year Period (2014) (35)
Initial lung transplantation experience with uncontrolled donation after cardiac death in North America (2020) (35)
A Multicenter Case-control Study of the Effect of Acute Rejection and Cytomegalovirus Infection on Pneumocystis Pneumonia in Solid Organ Transplant Recipients (2018) (34)
LAMIVUDINE FOR HEPATITIS B IN LIVER TRANSPLANTATION (2000) (34)
A strategy for prevention of fungal infections in lung transplantation: Role of bronchoalveolar lavage fluid galactomannan and fungal culture. (2018) (34)
A multicenter evaluation of pandemic influenza A/H1N1 in hematopoietic stem cell transplant recipients (2013) (32)
Prolonged Prophylaxis With Valganciclovir Is Cost Effective in Reducing Posttransplant Cytomegalovirus Disease Within the United States (2010) (30)
Canadian Society of Nephrology Commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis: management of glomerulonephritis in adults. (2014) (30)
A pilot randomized trial of adjuvanted influenza vaccine in adult allogeneic hematopoietic stem cell transplant recipients (2017) (30)
An Analysis of Regulatory T-Cell and Th-17 Cell Dynamics during Cytomegalovirus Replication in Solid Organ Transplant Recipients (2012) (29)
Neutralization of SARS-CoV-2 Variants in Transplant Recipients After Two and Three Doses of mRNA-1273 Vaccine (2021) (29)
An assessment of interactions between hepatitis C virus and herpesvirus reactivation in liver transplant recipients using molecular surveillance (2007) (28)
Microbial contamination of clinical islet transplant preparations is associated with very low risk of infection. (2013) (28)
Respiratory Viral Infections in Transplant and Oncology Patients (2010) (28)
Utility of a Monitoring Strategy for Human Herpesviruses 6 and 7 Viremia After Liver Transplantation: A Randomized Clinical Trial (2015) (28)
Immunogenicity of COVID-19 Vaccination in Immunocompromised Patients: An Observational, Prospective Cohort Study Interim Analysis (2021) (27)
Outbreak of pseudomonas aeruginosa by multiple organ transplantation from a common donor. (2003) (27)
Hcmv‐miR‐UL22A‐5p: A Biomarker in Transplantation With Broad Impact on Host Gene Expression and Potential Immunological Implications (2015) (27)
Identifying Predictors of Central Nervous System Disease in Solid Organ Transplant RecipientsWith Cryptococcosis (2010) (27)
A novel model to study bacterial adherence to the transplanted airway: inhibition of Burkholderia cepacia adherence to human airway by dextran and xylitol. (2004) (26)
Severe acute respiratory syndrome and the liver (2004) (26)
A randomised trial comparing cytomegalovirus antigenemia assay vs screening bronchoscopy for the early detection and prevention of disease in allogeneic bone marrow and peripheral blood stem cell transplant recipients (2001) (26)
Evaluation of a non-isotopic polymerase chain reaction-based assay to detect and predict treatment failure of Plasmodium vivax malaria in travellers. (1997) (25)
T-cell responses following Natural Influenza Infection or Vaccination in Solid Organ Transplant Recipients (2020) (24)
Implication of the intestinal microbiome in complications of cirrhosis (2016) (24)
Public Solicitation of Anonymous Organ Donors: A Position Paper by the Canadian Society of Transplantation (2017) (23)
Pancreas Islet Transplantation for Patients With Type 1 Diabetes Mellitus: A Clinical Evidence Review. (2015) (23)
Effect of organ donation after circulatory determination of death on number of organ transplants from donors with neurologic determination of death (2017) (23)
Non-nucleoside reverse transcriptase inhibitor failure impairs HIV-RNA responses to efavirenz-containing salvage antiretroviral therapy. (2001) (23)
Effect of cytomegalovirus infection on 1-year mortality rates among recipients of allogeneic bone marrow transplants. (1998) (23)
Effect of Immunosuppression on T-Helper 2 and B-Cell Responses to Influenza Vaccination. (2015) (21)
LILRB1 polymorphisms influence posttransplant HCMV susceptibility and ligand interactions (2018) (21)
Letermovir as Salvage Therapy for CMV Infection in Transplant Recipients. (2020) (21)
Impaired T Cell Responsiveness to Interleukin-6 in Hematological Patients with Invasive Aspergillosis (2015) (21)
Methicillin-resistant Staphylococcus aureus infection after lung transplantation: 5-year review of clinical and molecular epidemiology. (2009) (21)
Lessons Learned From a Randomized Study of Oral Valganciclovir Versus Parenteral Ganciclovir Treatment of Cytomegalovirus Disease in Solid Organ Transplant Recipients: The VICTOR Trial. (2016) (20)
Long Term Immune Responses to Pandemic Influenza A/H1N1 Infection in Solid Organ Transplant Recipients (2011) (20)
Disseminated Bartonella infection with granulomatous hepatitis in a liver transplant recipient. (1999) (20)
Potential transmission of viral hepatitis through use of stored blood vessels as conduits in organ transplantation--Pennsylvania, 2009. (2011) (19)
Outcomes from pandemic infl uenza A H 1 N 1 infection in recipients of solid-organ transplants : a multicentre cohort study (2010) (19)
Aspergillus galactomannan detection in exhaled breath condensate compared to bronchoalveolar lavage fluid for the diagnosis of invasive aspergillosis in immunocompromised patients. (2017) (18)
Letermovir as Salvage Therapy for Cytomegalovirus Infection in Transplant Recipients. (2020) (18)
Donor‐Derived Infection: Old Problem, New Solutions? (2008) (18)
The clinical utility of CMV surveillance cultures and antigenemia following bone marrow transplantation (1999) (17)
CCL8 and the Immune Control of Cytomegalovirus in Organ Transplant Recipients (2015) (17)
Predictors of Virological Response in HIV-Infected Patients to Salvage Antiretroviral Therapy that Includes Nelfinavir (2001) (17)
Graphium basitruncatum Fungemia in a Patient with Acute Leukemia (2007) (17)
Severe Legionnaire's disease caused by Legionella longbeachae in a long‐term renal transplant patient: the importance of safe living strategies after transplantation (2012) (16)
Pandemic Influenza and Its Implications for Transplantation (2006) (16)
Prospective Clinical, Virologic, and Immunologic Assessment of COVID-19 in Transplant Recipients (2021) (16)
Early post‐transplant vaccination with pandemic influenza A/H1N1 vaccine in pediatric heart transplant recipients (2010) (16)
Improving our mechanistic understanding of the indirect effects of CMV infection in transplant recipients (2019) (16)
Elimination of an outbreak of gram-negative bacteremia in a hemodialysis unit. (1996) (15)
Baseline serum interleukin-6 to interleukin-2 ratio is associated with the response to seasonal trivalent influenza vaccine in solid organ transplant recipients. (2015) (15)
Human cytomegalovirus infection in humanized liver chimeric mice (2013) (14)
Modulation of the Inhibitory Receptor Leukocyte Ig-Like Receptor 1 on Human Natural Killer Cells (2011) (14)
Ex-vivo delivery of monoclonal antibody (Rituximab) to treat human donor lungs prior to transplantation (2020) (14)
Ganciclovir Pharmacokinetic Parameters Do Not Change When Extending Valganciclovir Cytomegalovirus Prophylaxis From 100 to 200 Days (2010) (14)
Life-Threatening Infection in Transplant Recipients (2013) (13)
The AST Handbook of Transplant Infections (2011) (13)
Recommended curriculum for subspecialty training in transplant infectious disease on behalf of the American Society of Transplantation Infectious Diseases Community of Practice Educational Initiatives Working Group (2009) (13)
Prevention of hepatitis C virus infection using a broad cross‐neutralizing monoclonal antibody (AR4A) and epigallocatechin gallate (2015) (13)
Liver Transplantation for Acute Liver Failure Due to Dengue Fever (2019) (12)
Ex vivo Treatment of Cytomegalovirus in Human Donor Lungs Using a Novel Chemokine-Based Immunotoxin (2021) (12)
Prospective observational study and serosurvey of SARS-CoV-2 infection in asymptomatic healthcare workers at a Canadian tertiary care center (2021) (12)
Donor‐Specific Alloantibody Upregulation After Influenza Vaccination in Transplant Recipients (2011) (12)
A comparative study of the use of selective digestive decontamination prophylaxis in living‐donor liver transplant recipients (2014) (12)
Outcomes of SARS-CoV-2 Infection in Unvaccinated Compared With Vaccinated Solid Organ Transplant Recipients: A Propensity Matched Cohort Study (2022) (12)
Tuberculosis and transplantation: battling the opportunist. (2009) (12)
Letermovir Prophylaxis for Cytomegalovirus. (2018) (11)
Safety and Immunogenicity After a Three-Dose SARS-CoV-2 Vaccine Schedule in Allogeneic Stem Cell Transplant Recipients (2022) (11)
Treatment of Cytomegalovirus Disease in Solid Organ Transplant Recipients: Markers of Inflammation as Predictors of Outcome (2012) (11)
Differential decay kinetics of human cytomegalovirus glycoprotein B genotypes following antiviral chemotherapy☆ (2012) (11)
Evaluation of Recombinant Herpes Zoster Vaccine for Primary Immunization of Varicella-seronegative Transplant Recipients (2021) (11)
Failure of rituximab is associated with a poor outcome in diffuse large B cell lymphoma‐type post‐transplant lymphoproliferative disorder (2020) (11)
Novel decay dynamics revealed for virus-mediated drug activation in cytomegalovirus infection (2017) (11)
A Prospective Assessment of Cytomegalovirus Immune Evasion Gene Transcription Profiles in Transplant Patients With Cytomegalovirus Infection (2007) (11)
Peginterferon-lambda for the treatment of COVID-19 in outpatients (2020) (10)
Response to Questions Regarding the Design and Results of the IMPACT Trial (2011) (10)
Systemic immunosuppression in limbal stem cell transplantation: best practices and future challenges. (2018) (10)
Safety and immunogenicity of adjuvanted recombinant subunit herpes zoster vaccine in lung transplant recipients (2021) (10)
Incidence, Outcomes, and Long-term Immune Response to Tuberculosis in Organ Transplant Recipients (2019) (10)
Deep Profiling of the CD8+ T-cell Compartment Identifies Activated Cell Subsets and Multifunctional Responses Associated With Control of Cytomegalovirus Viremia (2019) (10)
Characterization of Cytomegalovirus Disease in Solid Organ Transplant Recipients by Markers of Inflammation in Plasma (2013) (9)
Ureaplasma spp. and Mycoplasma hominis PCR in Respiratory Samples from Lung Transplant Recipients with Hyperammonemia Syndrome and Cerebral Edema (2018) (9)
Short-course early outpatient remdesivir prevents severe disease due to COVID-19 in organ transplant recipients during the omicron BA.2 wave (2022) (9)
Risk factors for surgical site infection after kidney and pancreas transplantation (2018) (9)
Organ utilization from increased infectious risk donors: An observational study (2017) (9)
Heterologous Immune Responses to Influenza Vaccine in Kidney Transplant Recipients (2017) (8)
Clinical Utility Of Cytomegalovirus (CMV) Viral Load Determination For Predicting CMV Disease In Liver Transplant Recipients (1999) (8)
Late Onset Invasive Pulmonary Aspergillosis in Lung Transplant Recipients in the Setting of a Targeted Prophylaxis/Preemptive Antifungal Therapy Strategy (2020) (8)
The basis of liver regeneration: A systems biology approach. (2018) (8)
Drug-resistant cytomegalovirus infection after lung transplantation: Incidence, characteristics, and clinical outcomes. (2019) (8)
Diabetogenic Effects of Immunosuppression: An Integrative Analysis (2020) (8)
Strategies for safe living among lung transplant recipients: a single‐center survey (2015) (7)
The AST Handbook of Transplant Infections: Kumar/The AST Handbook of Transplant Infections (2011) (7)
SARS-CoV-2 differs from SARS-CoV in the requirements for receptor expression and proteolytic activation to trigger cell-cell fusion and is not inhibited by Bromhexine (2020) (7)
Clinical and virologic outcomes in high‐risk adult Epstein‐Barr virus mismatched organ transplant recipients (2017) (7)
Control of microbial contamination during surgical harvest of pig renal xenografts (2004) (7)
Cell-Mediated Immune Responses after Influenza Vaccination of Solid Organ Transplant Recipients: a Secondary Outcomes Analysis of a Randomized Controlled Trial. (2019) (7)
Quinolone prophylaxis for the prevention of BK virus infection in kidney transplantation: study protocol for a randomized controlled trial (2013) (7)
Lung transplantation for severe antineutrophilic cytoplasmic antibody-associated vasculitis. (2010) (6)
A Survey of Increased Infectious Risk Donor Utilization in Canadian Transplant Programs (2016) (6)
Discipline of Transplant Infectious Diseases (ID). Foreword. (2009) (6)
Successful lung transplant in a child with cystic fibrosis and persistent Blastobotrys rhaffinosifermentans infection (2014) (6)
Successful bilateral lung transplantation in a patient with end-stage lung disease and positive novel influenza virus (H1N1). (2010) (6)
Prospective Observational Study of Screening Asymptomatic Healthcare Workers for SARS-CoV-2 at a Canadian Tertiary Care Center (2020) (6)
Tacrolimus Impairs Kupffer Cell Capacity to Control Bacteremia: Why Transplant Recipients Are Susceptible to Infection (2020) (6)
Time to Consider Cytomegalovirus Prevention in Critically Ill Patients? (2017) (6)
Humoral response to natural influenza infection in solid organ transplant recipients (2019) (6)
Feasibility of Detecting Fungal DNA in Exhaled Breath Condensate by the Luminex Multiplex xTAG Fungal PCR Assay in Lung transplant Recipients: A Pilot Study (2016) (6)
Human MicroRNA Responses Predict Cytomegalovirus Replication Following Solid Organ Transplantation (2016) (6)
Impact of Vaccination and Early Monoclonal Antibody Therapy on Coronavirus Disease 2019 (COVID-19) Outcomes in Organ Transplant Recipients During the Omicron Wave (2022) (5)
Delayed interval BNT162b2 mRNA COVID-19 vaccination provides robust immunity (2021) (5)
Chronic Candida dubliniensis meningitis in a lung transplant recipient (2019) (5)
Natural influenza infection produces a greater diversity of humoral responses than vaccination in immunosuppressed transplant recipients (2021) (5)
Buyer beware: The risks of donor-derived vaccine-induced thrombosis and thrombocytopenia (2021) (5)
Transplantation: Cytomegalovirus prophylaxis: how long is enough? (2010) (5)
Complexity of Host Micro‐RNA Response to Cytomegalovirus Reactivation After Organ Transplantation (2016) (5)
Increased Osteoprotegerin Predicts Poor Virological Outcome During Anticytomegalovirus Therapy in Solid Organ Transplant Recipients (2015) (5)
Impact of immunosuppression on the immune response to SARS‐CoV‐2 infection: A mechanistic study (2021) (5)
Homotypic and heterotypic immune responses to Omicron variant in immunocompromised patients in diverse clinical settings (2022) (4)
Autologous Hematopoietic Stem Cell Transplantation for Liver Transplant Recipients With Recurrent Primary Sclerosing Cholangitis: A Pilot Study (2021) (4)
Utility of Cytomegalovirus Cell-Mediated Immunity Assays in Solid Organ Transplantation (2022) (4)
Natural history of recurrent hepatitis C after liver transplantation. (2001) (4)
Potential role of CC chemokine receptor 6 in prediction of late‐onset cytomegalovirus infection following solid organ transplant (2015) (4)
Echinocandin use in lung transplant recipients (2018) (4)
An international survey of mycobacterium abscessus infections in lung transplant recipients (2005) (4)
CMV immune monitoring—Where do we go from here? (2020) (4)
Severe Acute Respiratory Syndrome Coronavirus 2 Infection Induces Greater T-Cell Responses Compared to Vaccination in Solid Organ Transplant Recipients (2021) (4)
Screening for West Nile Virus: More Uncertainty (2004) (4)
Pancreas transplantation: indications, clinical management, and outcomes. (1997) (4)
Humoral Immune Response following Seasonal Influenza Vaccine in Islet Transplant Recipients (2013) (4)
Clinical predictors of progression and clearance of low‐level CMV DNAemia in solid organ transplant recipients (2020) (4)
A Clinical Trial Evaluating the Effects of Ultra-Violet C treatment (UVC) during Ex Vivo Lung Perfusion (EVLP) as a Method of Inactivating Hepatitis C Infection in Donor Lungs (2019) (3)
Targeting Latent Human Cytomegalovirus (CMV) with a Novel Fusion Toxin Protein during Ex Vivo Lung Perfusion. (2020) (3)
Cytomegalovirus Prevention: Prophylaxis and Preemptive Therapy (2007) (3)
Latent Tuberculosis Infection: Is Universal Screening the Right Approach? (2014) (3)
Assessment of Cytomegalovirus-Speci fi c Cell-Mediated Immunity for the Prediction of Cytomegalovirus Disease in High-Risk Solid-Organ Transplant Recipients : A Multicenter Cohort Study (2013) (2)
Valganciclovir for cytomegalovirus prevention and treatment (2005) (2)
Risks and Epidemiology of Infections After Pancreas or Kidney–Pancreas Transplantation (2016) (2)
Cytokine Profiles and Severity of Influenza Infection in Transplant Recipients (2018) (2)
Late‐onset allograft rejection, cytomegalovirus infection, and renal allograft loss: Is anti‐CMV prophylaxis required following late‐onset allograft rejection? (2021) (2)
A Pilot Randomized Controlled Trial of Adjuvanted Versus Nonadjuvanted Influenza Vaccine in Adult Allogeneic Hematopoietic Stem Cell Transplant Recipients (2016) (2)
Characterization and predictive functional profiles on metagenomic 16S rRNA data of liver transplant recipients: A longitudinal study (2021) (2)
Cytomegalovirus in the transplant setting: Where are we now and what happens next? A report from the International CMV Symposium 2021 (2022) (2)
Cytomegalovirus in the Pediatric Transplant Recipient: Where Are We Now? (2017) (2)
The economic impact of increased length of stay associated with surgical site infections in liver transplantation on Canadian healthcare costs (2020) (2)
LB2307. Safety and Efficacy of Letermovir (LET) versus Valganciclovir (VGCV) for Prevention of Cytomegalovirus (CMV) Disease in Kidney Transplant Recipients (KTRs): A Phase 3 Randomized Study (2022) (2)
Cytokine profile in lung transplant recipients with Aspergillus spp colonization (2019) (2)
Understanding risk and enhancing safety in immunotherapy trials. (2013) (1)
Randomized Trial of a MF-59 Adjuvanted Influenza Vaccine in Kidney Transplant Recipients.: Abstract# D2380 (2014) (1)
Preventing CMV Viremia and Disease 3–6 Months After Renal Transplantation (2010) (1)
Transplantation of NAT+HCV Donor Lungs into Non-Infected Recipients Followed by Treatment with Sofosbuvir/Velpatasvir (S/V) (2019) (1)
INADEQUATE EMPIRIC ANTIBIOTIC THERAPY AMONG SOLID-ORGAN TRANSPLANT PATIENTS: INCIDENCE AND IMPACT ON HOSPITAL MORTALITY. (2006) (1)
A Randomized Controlled Trial Comparing Intradermal vs. Intramuscular Influenza Vaccine in Lung Transplant Recipients (2010) (1)
Testing the delivery of human organ transportation with drones in the real world (2022) (1)
(304) – Utility of Droplet Digital PCR for the Detection of Aspergillus DNA in Bronchoalveolar Lavage and Exhaled Breath Condensate Samples from Lung Transplant Recipients (2017) (1)
Donor Screening for Human T‐Cell Lymphotrophic Virus 1/2: The future Is Uncertain (2010) (1)
Reply to Dunbar et al. (2019) (1)
INFECTIOUS COMPLICATIONS IN LIVER TRANSPLANT RECIPIENTS TRANSPLANTED FOR HEPATITIS C.: Abstract# 603 (2000) (1)
Severity of COVID-19 among solid organ transplant recipients in Canada, 2020–2021: a prospective, multicentre cohort study (2022) (1)
Evaluation of a gene expression biomarker to identify operationally tolerant liver transplant recipients: the LITMUS trial (2021) (1)
A cross-Canada survey of cytomegalovirus prevention and treatment practices in bone marrow transplant recipients. (1999) (1)
American Transplant Congress 2007 Executive and Program Planning Committees and Abstract Review Committees (2007) (1)
Long‐lasting cluster of nosocomial pneumonia with a single Pneumocystis jirovecii genotype involving different organ allograft recipients (2020) (1)
BK virus prophylaxis with levofloxacin--reply. (2015) (1)
NK Cell Immunity Pre‐Transplant as a Predictor for CMV Post‐Transplant.: Abstract# 2167 (2014) (1)
Infections in Kidney Transplant Recipients (2016) (1)
PUK16 COST-EFFECTIVENESS OF VALGANCICLOVIR 200 DAYS PROPHYLAXIS VERSUS 100 DAYS PROPHYLAXIS IN KIDNEY TRANSPLANT PATIENTS AT HIGH-RISK FOR DEVELOPING CYTOMEGALOVIRUS DISEASE (2011) (1)
T-cell responses following Natural Influenza Infection or Vaccination in Solid Organ Transplant Recipients (2020) (0)
Estimates of Window Period Length for Serology and Nucleic Acid Testing (2011) (0)
A Randomized Trial of High-dose Influenza Vaccine in Adult Solid-Organ Transplant Recipients (2017) (0)
High-throughput sequencing defines donor and recipient HLA B-cell epitope frequencies for prospective matching in transplantation (2021) (0)
Authorsʼ Reply: Why Valganciclovir Should Not Be Indicated for Liver Recipients and High-Dose Acyclovir Should Not Be Removed From International Cytomegalovirus Guidelines (2011) (0)
FRI-226-Modeling early viral kinetics during observed HCV acute infection in post lung transplantation recipients (2019) (0)
Molecular identification of Aspergillus fumigatus complex from lung transplant recipients using multilocus sequencing analysis (MLSA). (2022) (0)
Incidence of Post-Transplant Cytomegalovirus Viremia in Patients Receiving Lungs After Ex Vivo Lung Perfusion (2022) (0)
Estimates of Residual Risk of HIV or HCV when Using Selected Increased Risk Donor Categories (2011) (0)
1532. Increased Risk of Bacterial, Fungal and Other Viral Infections During CMV Infection: Decreased Cytokine Production in Response to Toll-Like Receptor Ligands (2018) (0)
A DOUBLE-BLIND RANDOMIZED TRIAL OF A PRIMING STRATEGY USING PNEUMOCOCCAL CONJUGATE VACCINE IN ADULT LIVER TRANSPLANT RECIPIENTS. (2006) (0)
Treatment of Cytomegalovirus in Human Donor Lungs with a Novel Chemokine-Based Immunotoxin during Ex Vivo Lung Perfusion Prevents Viral Reactivation (2021) (0)
Impact of Omicron BA.1 infection on BA.4/5 immunity in transplant recipients (2022) (0)
Innate and Adaptive Immune Correlates of Chronic and Self-limiting EBV DNAemia in Solid-organ Transplant Recipients (2020) (0)
QuantiFERON testing for cell-mediated immunity to cytomegalovirus in patients with rheumatoid arthritis receiving abatacept and other DMARD therapy (2013) (0)
Lamivudine (3TC) for Hepatitis B in Liver Transplantation: The Toronto Hospital Experience. (1999) (0)
Predictive Cytokine Profile for Invasive Aspergillosis in Lung Transplant Recipients in the Setting of Pre-emptive Prophylaxis (2018) (0)
Solid Organ Transmitted Infections (2006) (0)
(237) - A.fumigatus CYP51A Mutations in Lung Transplant Recipients (2017) (0)
Paucisymptomatic COVID-19 in lung transplant recipient following two doses of mRNA-1273 (Moderna) vaccine (2021) (0)
Ex-Vivo Lung Perfusion Mediated Delivery of Rituximab to Clear Latent Epstein-Barr Virus (2019) (0)
CONCISE COMMUNICATIONS Elevated Serum Cytokines Are Associated with Cytomegalovirus Infection and Disease in Bone Marrow Transplant Recipients (1999) (0)
CASE REPORTS Graphium basitruncatum Fungemia in a Patient with Acute Leukemia (2007) (0)
Reply to Hamilton. (2018) (0)
Omicron BA.4/5 neutralization and T-cell responses in organ transplant recipients after Booster mRNA vaccine: a Multicenter Cohort Study. (2023) (0)
Simkania negevensis and Chronic Lung Allograft Dysfunction in Lung Transplant Recipients (2018) (0)
American Transplant Congress 2008 Program Planning Committees (2008) (0)
The University of Toronto Liver Transplant Program: Toronto General Hospital, Hospital for Sick Children. (2000) (0)
The Basis of Liver Regeneration: A Systems Biology Approach (2018) (0)
Approaches to emerging infectious pathogens in cardiothoracic transplantation and mechanical circulatory support (2011) (0)
CMV: The Eternal Challenge (2018) (0)
NATURAL HISTORY OF RUCURRENT HEPATITIS C AFTER LIVER TRANSPLANTATION.: Abstract# 772 Poster Board #‐Session: P29‐III (2000) (0)
Immunogenicity, Safety, and Breakthrough SARS-CoV-2 infections after COVID-19 Vaccination in Organ Transplant Recipients: A Prospective Multicenter Canadian Study (2023) (0)
Fatal falciparum malaria in Canadian travellers. (1997) (0)
Foreword (2009) (0)
Impact of Immunosuppression on the Metagenomic Composition of the Intestinal Microbiome: a Systems Biology Approach to Post-Transplant Diabetes (2017) (0)
Response to Correspondence on Outcomes of COVID-19 in Unvaccinated Compared With Vaccinated Solid Organ Transplant Recipients (2022) (0)
Incidence and Outcomes of Active Tuberculosis In Solid Organ Transplant Recipients: A 16-Year Review (2016) (0)
Management of refractory and resistant CMV: A step forward but more work needed (2021) (0)
Evaluating the Role of STAT3 in CD4+ T Cells in Susceptibility to Invasive Aspergillosis (2021) (0)
Outbreak of Pseudomonas aeruginosa via multiple organ transplantation from a common donor (2002) (0)
Correction: Novel decay dynamics revealed for virus-mediated drug activation in cytomegalovirus infection (2017) (0)
Utility of a Monitoring Strategy for Human Herpesviruses 6 and 7 Viremia in Liver Transplant Recipients: A Randomized Clinical Trial.: Abstract# D2402 (2014) (0)
Post transplant lymphoproliferative disorder in liver transplant patients (2001) (0)
Response to: Larger Dose of Intradermal Influenza Vaccination May Be More Immunogenic in Transplant Recipients (2008) (0)
Differential serum neutralisation of omicron sublineages in patients receiving prophylaxis with tixagevimab–cilgavimab (2023) (0)
Parallel Sessions 1–15 (2007) (0)
(620) - Correlation of Radiological Imaging with Microbiological Cure or Mortality from Invasive Pulmonary Aspergillosis (IPA) in Lung Transplant Recipients (LTRs) (2017) (0)
Prevention and Treatment of CMV Infection (and Other Herpes Viruses) (2019) (0)
A Single-Center Retrospective Study of 140 Patients with Post-Transplant Lymphoproliferative Disorder Following Solid Organ Transplantation (2016) (0)
Reply to Dunbar, Schauwvlieghe and Rijnders (2019) (0)
Molecular Identification of Aspergillus Fumigatus Complex from Lung Transplant Recipients Using Multi Locus Sequencing Analysis (MLSA). (2020) (0)
Emerging Viruses and Transplantation (2004) (0)
Late Onset Invasive Pulmonary Aspergillosis in Lung Transplant Recipients Treated with a Preemptive/ Targeted Antifungal Therapy Strategy: 4 Year Follow Up (2019) (0)
Inactivating hepatitis C virus in donor lungs using light therapies during normothermic ex vivo lung perfusion (2019) (0)
Drug Resistant CMV Infection in Lung Transplantation Patients: Incidence, Characteristics and Clinical Outcomes (2019) (0)
THE IMPACT STUDY: VALGANCICLOVIR PHARMACOKINETIC PARAMETERS DO NOT CHANGE WHEN EXTENDING PROPHYLAXIS FROM 100 TO 200 DAYS.: 995 (2010) (0)
CMV-Specific T Cell Responses Predict the Risk of CMV Viremia After Discontinuation of Prophylaxis in SOT.: Abstract# D2682 (2014) (0)
HUMAN CYTOMEGALOVIRUS INFECTION IN HUMANIZED LIVER CHIMERIC MICE: 1191 (2010) (0)
Prevention of CMV: New developments (2009) (0)
Epidemiology and Clinical Impact of Blood, Cell, Tissue, and Organ Donor Transmitted Infections (2017) (0)
Aspergillus Galactomannan Detection in Exhaled Breath Condensate for the Diagnosis of Invasive Aspergillosis in Lung Transplant Recipients (2017) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Atul Humar?

Atul Humar is affiliated with the following schools:

University of Alberta
University of British Columbia
University of Toronto

Atul Humar's Academic­Influence.com Rankings

Why Is Atul Humar Influential?

Atul Humar's Published Works

Published Works

What Schools Are Affiliated With Atul Humar?

Atul Humar's AcademicInfluence.com Rankings